- Home
- MVO vs RVPH Comparison
MVO vs RVPH Comparison
Compare MVO & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MVO | RVPH |
|---|---|---|
| Founded | 2006 | 2006 |
| Country | United States | United States |
| Employees | N/A | 14 |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.3M | 29.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | MVO | RVPH |
|---|---|---|
| Price | $2.17 | $0.83 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $66.67 |
| AVG Volume (30 Days) | 571.9K | ★ 2.5M |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | ★ 17.46% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.46 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.47 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.97 | $0.17 |
| 52 Week High | $6.40 | $3.11 |
Technical Indicators
Market Signals| Indicator | MVO | RVPH |
|---|---|---|
| Relative Strength Index (RSI) | 48.63 | 44.73 |
| Support Level | $1.11 | $0.32 |
| Resistance Level | $2.42 | N/A |
| Average True Range (ATR) | 0.29 | 0.25 |
| MACD | -0.05 | -0.17 |
| Stochastic Oscillator | 7.22 | 22.10 |
Price Performance
Historical ComparisonAbout MVO MV Oil Trust Units of Beneficial Interests
MV Oil Trust is a statutory trust. Its underlying properties consist of MV Partners, LLC's (MV Partners) net interests in all of its oil and natural gas properties, which are located in the Mid-Continent region in the States of Kansas and Colorado. These properties include producing oil and gas wells.
About RVPH Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.